{"analyses":[{"ciLowerLimit":"0.40","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.72","estimateComment":"Hazard ratio \\<1 favours olaparib.","groupDescription":"Supportive analysis to PFS2.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.54","statisticalComment":"Stratified by received prior chemotherapy for metastatic breast cancer (yes/no) and receptor status.","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.3","upperLimit":"15.7","value":"14.3"},{"groupId":"OG001","lowerLimit":"8.5","upperLimit":"11.3","value":"10.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"205"},{"groupId":"OG001","value":"97"}],"units":"Participants"}],"description":"Time from randomisation to the earliest of second subsequent cancer therapy start date following study treatment discontinuation, or death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Olaparib 300 mg bd tablets","id":"OG000","title":"Olaparib 300 mg bd"},{"description":"Physician's choice of chemotherapy; capecitabine, vinorelbine, or eribulin","id":"OG001","title":"Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set (FAS) consisting of all randomised patients","reportingStatus":"POSTED","timeFrame":"Subsequent cancer therapy status reviewed every 8 weeks following study treatment discontinuation until Sep 2017 (final OS DCO), then every 3 months. Assessed up to a maximum of 64 months.","title":"Time to Second Subsequent Cancer Therapy or Death (TSST) at Extended OS","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Months"}